Influence of Severe Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Ximelagatran and Subcutaneous Melagatran
- 1 January 2003
- journal article
- clinical trial
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 42 (8), 743-753
- https://doi.org/10.2165/00003088-200342080-00003
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Ximelagatran versus warfarin forstroke prevention in patientswith nonvalvular atrial fibrillation: SPORTIF ii: a dose-guiding, tolerability, and safety studyJournal of the American College of Cardiology, 2003
- Pharmacokinetics of Melagatran and the Effect on Ex Vivo Coagulation Time in Orthopaedic Surgery Patients Receiving Subcutaneous Melagatran and Oral XimelagatranClinical Pharmacokinetics, 2003
- Influence of Age on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin InhibitorClinical Pharmacokinetics, 2003
- A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE IJournal of Thrombosis and Haemostasis, 2003
- Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trialThe Lancet, 2002
- Ximelagatran versus Warfarin for the Prevention of Venous Thromboembolism after Total Knee ArthroplastyAnnals of Internal Medicine, 2002
- Measurement of renal function during drug developmentBritish Journal of Clinical Pharmacology, 2002
- Comparison of the Oral Direct Thrombin Inhibitor Ximelagatran With Enoxaparin as Prophylaxis Against Venous Thromboembolism After Total Knee ReplacementArchives of Internal Medicine, 2001
- New Anticoagulant DrugsChest, 2001
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976